• 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br In summary our studies showed that AHN induced p


    In summary, our studies showed that 8-AHN induced p53 expression and transcriptional activity, subsequently elevating the expression of p53 target genes, and induced colorectal cancer Sotrastaurin (AEB071) arrest and apoptosis subsequently. Moreover, our studies in vivo showed that treatment with 8-AHN significantly suppressed the growth of HCT116 cancer xenograft tumors, associated with proliferation suppression and apoptosis induction in tumor tissues, without inducing any notable major organ-related toxicity. All these data provide evidence for the development of 8-AHN as a potential chemotherapeutic agent for col-orectal cancer and for further research and development.
    Author contributions section
    Jun Du, Sheng Yin and Hongsheng Wang: Conceptualization, formal analysis, funding acquisition, software, and writing - review and edit; Jiawang Zhou, Ziqian Li and Junjie Zhang: Data curation, writing - original draft, and writing - review and editing; Jiawang Zhou, and Ziqian Li: Methodology, project administration.
    The authors would like to thank for Professor Sheng Yin (Sun Yat-sen University) for his help with the separation and identification of 8-AHN. This work was supported by the National Science Foundation of China (Nos. 81472643 and 81672943).
    Appendix A. Supplementary data
    The authors declare no conflicts of interest.
    Abraham, R.T., 2001. Cell cycle checkpoint signaling through the ATM and ATR kinases.
    Antiangiogenic phytochemicals and medicinal herbs. Phytother Res. 25, 1–10.
    264 Original Study
    8-Hydroxy-2’-deoxyguanosine as a Discriminatory Biomarker for Early Detection of Breast Cancer
    Essam Eldin Mohamed Nour Eldin,1 Mahmoud Zaki El-Readi,1,2 Mohamed Mahmoud Nour Eldein,1,3 Albagir Ali Alfalki,4 Mohammad Ahmad Althubiti,1 Hala Fawzy Mohamed Kamel,1,3 Safaa Yehia Eid,1 Hiba Saeed Al-Amodi,1 Ahmad A. Mirza5
    For early detection of malignant tumors, serum levels of 8-hydroxy-2’-deoxyguanosine were determined in 50 women with benign breast tumors, 50 women with breast cancer (BC), and 50 healthy women as a control group. 8-hydroxy-2’-deoxyguanosine levels were significantly increased in the BC group compared with the benign tumor and the healthy control groups; thus pacemaker can be used as a potential noninvasive biomarker for early detection of BC.
    Background: Breast cancer (BC) is one of the most prevalent and reported cancers among Saudi women. Detection of BC in the early invasive stage (stages I, II) has an advantage in treating patients over detection in the late invasive stage (stages III, IV). Tumor markers are used to aid in diagnosis, treatment monitoring, and recurrence detection of malignant tumors. 8-hydroxy-2’-deoxyguanosine (8-OHdG) is a marker of nucleic damage owing to oxidative stress. Patients and Methods: We studied the blood levels of 8-OHdG in 50 women with benign breast tumors, 50 women with BC, and 50 healthy women as a control group. Results: The concentrations of 8-OHdG were significantly increased in the BC group (55.2 ng/dL) compared with the benign tumor group (30.2 ng/dL) and with the healthy control group (9.08 ng/dL). The same pattern was observed with other diagnostic markers, including carcinoembryonic antigen and cancer antigen 15-3. Significant positive correlations between 8-OHdG and both carcinoembryonic antigen (r ¼ 0.63; P < .001) and cancer antigen 15-3 (r ¼ 0.51; P < .001) were noticed. The levels of 8-OHdG were significantly higher in stage I (81 ng/dL) compared with stage II (51 ng/dL; P < .05), stage III (38 ng/dL; P < .01), and stage IV (19 ng/dL; P < .001). In addition, serum 8-OHdG had a high diagnostic performance in BC (area under the curve, 0.86; sensitivity ¼ 82%; specificity ¼ 80% at cutoff value 21.4 ng/mL). 8-OHdG is associated with BC risk according to logistic regression analysis. Conclusion: We concluded that the significant increase of serum levels of 8-OHdG in patients with BC can be used as a potential noninvasive biomarker for early detection of BC. However, large sample sizes from different stages and types of BC should be included in any future study to confirm the present findings before translating the findings into routine clinical application.